Type 1 Diabetes Clinical Trial Landscape
Data updated: May 20, 2026
806 clinical trials tracked since 2008
Type 1 Diabetes is a chronic autoimmune condition where the pancreas produces little to no insulin, a hormone needed to allow sugar (glucose) to enter cells to produce energy. This condition typically appears in childhood or adolescence, but can develop in adults. The clinical trial landscape for Type 1 Diabetes demonstrates significant activity, with 805 trials registered since 2008, and 126 currently active. Activity is heavily concentrated in Phase 1 and Phase 2 trials, with 32 and 72 active trials respectively, compared to 28 active Phase 3 trials and 17 active Phase 4 trials. This suggests a strong focus on early-stage development and proof-of-concept studies. Eli Lilly leads industry sponsorship of active trials with 6, followed by Sanofi with 5, and Novo Nordisk and Vertex Pharmaceuticals Incorporated, each with 3. Diamyd Medical AB is also an active sponsor, with 2 ongoing trials.
122 active
/
806 total (since 2008)
32
Phase 1 Active
297 total
67
Phase 2 Active
322 total
27
Phase 3 Active
178 total
16
Phase 4 Active
102 total
Top Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 6 43 3
Sanofi 5 31 2
Novo Nordisk 4 85 1
Vertex Pharmaceuticals Incorporated 3 0 0
Diamyd Medical AB 2 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06914895 ACTIVE NOT RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company n=905
NCT06334133 RECRUITING
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
vTv Therapeutics n=150
NCT07088068 RECRUITING
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi n=723
NCT07548996 RECRUITING
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
Nanjing Medical University n=96
NCT07222137 RECRUITING
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Eli Lilly and Company n=150
+ 173 more Phase 3 trials — see full database below
Type 1 Diabetes — Trials Started by Year (last 10 years)
2016 47
2017 46
2018 36
2019 53
2020 34
2021 33
2022 31
2023 35
2024 26
2025 38
2026 24
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Eli Lilly 52
Sanofi 38
Novo Nordisk 90
Vertex Pharmaceuticals Incorporated 3
Diamyd Medical AB 3
Mannkind Corporation 12
Gan and Lee Pharmaceuticals, USA 6
Zucara Therapeutics Inc. 2
vTv Therapeutics 2
SAb Biotherapeutics, Inc. 1
Active Trials by Phase
Phase 1 32
Phase 2 67
Phase 3 27
Phase 4 16
Enrollment Size Distribution
1-50 461
51-200 213
201-500 62
501-1k 27
1k+ 9
All Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 6 43 3
Sanofi 5 31 2
Novo Nordisk 4 85 1
Vertex Pharmaceuticals Incorporated 3 0 0
Diamyd Medical AB 2 1 0
Mannkind Corporation 1 9 2
Gan and Lee Pharmaceuticals, USA 1 4 1
Zucara Therapeutics Inc. 1 0 1
vTv Therapeutics 1 1 0
SAb Biotherapeutics, Inc. 1 0 0
GentiBio, Inc 1 0 0
COUR Pharmaceutical Development Company, Inc. 1 0 0
Portal Diabetes, Inc. 1 0 0
Immunocore Ltd 1 0 0
Mozart Therapeutics Australia Pty Ltd 1 0 0
NCT06914895 ACTIVE NOT RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company n=905
NCT06334133 RECRUITING
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
vTv Therapeutics n=150
NCT07088068 RECRUITING
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi n=723
NCT07548996 RECRUITING
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
Nanjing Medical University n=96
NCT07222137 RECRUITING
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Eli Lilly and Company n=150
NCT07222332 RECRUITING
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Eli Lilly and Company n=300
NCT05018585 ACTIVE NOT RECRUITING
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Diamyd Medical AB n=321
NCT07076199 RECRUITING
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Novo Nordisk A/S n=877
NCT06832410 RECRUITING
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Vertex Pharmaceuticals Incorporated n=10
NCT04786262 RECRUITING
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Vertex Pharmaceuticals Incorporated n=52
NCT07258394 RECRUITING
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus
Nanjing Medical University n=90
NCT05819138 RECRUITING
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
University of Colorado, Denver n=60
NCT06962280 ACTIVE NOT RECRUITING
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company n=465
NCT06630585 RECRUITING
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
University of Bern n=42
NCT01320345 ACTIVE NOT RECRUITING
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
University of Sydney n=412
NCT07284511 NOT YET RECRUITING
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
Melissa-Rosina Pasqua n=105
NCT04583462 ACTIVE NOT RECRUITING
Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes
Assistance Publique - Hôpitaux de Paris n=230
NCT07211802 NOT YET RECRUITING
CKM For Safe Use of SGLT2i in Type 1 Diabetes
University of California, San Diego n=52
NCT06909006 NOT YET RECRUITING
Semaglutide Treatment in Type 1 Diabetes
Nordsjaellands Hospital n=122
NCT06951074 RECRUITING
Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes
Ain Shams University n=20
NCT03899402 ACTIVE NOT RECRUITING
Triple Therapy in T1DM
State University of New York at Buffalo n=78
NCT03941132 ACTIVE NOT RECRUITING
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
University of British Columbia n=66
NCT06082063 RECRUITING
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Steno Diabetes Center Copenhagen n=2,000
NCT06387199 RECRUITING
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
McGill University Health Centre/Research Institute of the McGill University Health Centre n=26
NCT01897688 ACTIVE NOT RECRUITING
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
Northwestern University n=40
NCT04333823 ACTIVE NOT RECRUITING
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
The Hospital for Sick Children n=100
NCT05219409 NOT YET RECRUITING
Effects of Sitagliptin in Relatives of T1D Patients
University of Milan n=70
NCT07282054 COMPLETED
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd n=550
NCT04588259 COMPLETED
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Novo Nordisk A/S n=331
NCT04848480 COMPLETED
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
Novo Nordisk A/S n=582
NCT06418880 COMPLETED
Automated Insulin Delivery for Inpatients With Dysglycemia
Emory University n=130
NCT05901831 COMPLETED
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Bayer n=241
NCT04429503 COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals n=660
NCT07070752 COMPLETED
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
Geropharm n=224
NCT05378672 COMPLETED
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Zealand Pharma n=8
NCT05463744 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Eli Lilly and Company n=692
NCT02936843 COMPLETED
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
University of Michigan n=61
NCT04409795 COMPLETED
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
Joslin Diabetes Center n=3
NCT05205928 COMPLETED
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
McGill University Health Centre/Research Institute of the McGill University Health Centre n=28
NCT02897219 COMPLETED
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
Astellas Pharma Inc n=175
NCT03046927 COMPLETED
Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
Benjamin U. Nwosu, MD n=48
NCT03371082 COMPLETED
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Gan and Lee Pharmaceuticals, USA n=576
NCT03875729 COMPLETED
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Provention Bio, Inc. n=328
NCT03874715 COMPLETED
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=210
NCT06348706 COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Ain Shams University n=60
NCT02518945 COMPLETED
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
University at Buffalo n=26
NCT01722266 COMPLETED
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
University at Buffalo n=72
NCT00920582 TERMINATED
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
MacroGenics n=254
NCT04049110 COMPLETED
Dapagliflozin in Physical Exercise in Type 1 Diabetes
Insel Gruppe AG, University Hospital Bern n=39
NCT03174522 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Ixaka Ltd n=49
NCT04035031 COMPLETED
Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes
Insel Gruppe AG, University Hospital Bern n=13
NCT05467514 COMPLETED
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
David Sanchez Garcia n=35
NCT03895697 COMPLETED
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
Zealand Pharma n=92
NCT03952130 COMPLETED
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
Eli Lilly and Company n=354
NCT00949221 COMPLETED
Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)
Assistance Publique - Hôpitaux de Paris n=150
NCT03377699 COMPLETED
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
Novo Nordisk A/S n=225
NCT03262116 TERMINATED
Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
Massachusetts General Hospital n=20
NCT02735044 COMPLETED
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Sanofi n=463
NCT02666430 COMPLETED
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
Mylan Inc. n=127
NCT02227862 COMPLETED
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
Mylan Inc. n=558
NCT03740919 COMPLETED
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
Eli Lilly and Company n=751
NCT01816165 COMPLETED
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
University of Colorado, Denver n=28
NCT04932213 COMPLETED
Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients
Semnan University of Medical Sciences n=98
NCT01808690 COMPLETED
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
University of Colorado, Denver n=52
NCT03378635 COMPLETED
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
Zealand Pharma n=170
NCT03688711 COMPLETED
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
Zealand Pharma n=45
NCT04879511 COMPLETED
Effect of Metformin in Children With Type 1 Diabetes
Ain Shams University n=80
NCT03111238 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Ixaka Ltd n=3
NCT03216226 COMPLETED
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
Zealand Pharma n=112
NCT03911843 COMPLETED
Omega-3 and Vitamin D Supplements in Childhood T1D
Azienda Ospedaliero Universitaria Maggiore della Carita n=64
NCT03338023 COMPLETED
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
Eli Lilly and Company n=272
NCT01616784 COMPLETED
The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial
Sheffield Teaching Hospitals NHS Foundation Trust n=267
NCT03830281 COMPLETED
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
Eli Lilly and Company n=471
NCT03977727 COMPLETED
FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump
Texas Diabetes & Endocrinology, P.A. n=40
NCT04079413 COMPLETED
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
Geropharm n=264
NCT03738865 COMPLETED
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
Xeris Pharmaceuticals n=132
NCT03214367 COMPLETED
A Study of LY900014 in Participants With Type 1 Diabetes
Eli Lilly and Company n=1,392
NCT00684658 COMPLETED
TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes
Yale University n=320
NCT01881828 COMPLETED
Metformin Therapy for Overweight Adolescents With Type 1 Diabetes
Jaeb Center for Health Research n=164
NCT03263494 COMPLETED
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
Jaeb Center for Health Research n=153
NCT03439072 COMPLETED
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
Xeris Pharmaceuticals n=81
NCT02384941 COMPLETED
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Lexicon Pharmaceuticals n=793
NCT02531035 COMPLETED
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
Lexicon Pharmaceuticals n=1,405
NCT02421510 COMPLETED
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Lexicon Pharmaceuticals n=782
NCT04254380 WITHDRAWN
Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro
Gan and Lee Pharmaceuticals, USA
NCT01148680 COMPLETED
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment
University Hospital, Grenoble n=50
NCT01753362 COMPLETED
Liraglutide In Overweight Patients With Type 1 Diabetes
University at Buffalo n=84
NCT03840278 COMPLETED
The Bihormonal iLet Bionic Pancreas Feasibility Study
Massachusetts General Hospital n=12
NCT02825251 COMPLETED
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
Novo Nordisk A/S n=472
NCT02018627 COMPLETED
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
Steven J. Russell, MD, PhD n=20
NCT01994746 COMPLETED
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Eli Lilly and Company n=77
NCT04022993 COMPLETED
Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients
Geropharm n=180
NCT01483560 COMPLETED
REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
University of Glasgow n=493
NCT01513473 COMPLETED
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Novo Nordisk A/S n=350
NCT01831765 COMPLETED
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
Novo Nordisk A/S n=1,290
NCT02500706 COMPLETED
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Novo Nordisk A/S n=1,108
NCT01835431 COMPLETED
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Novo Nordisk A/S n=362
NCT02670915 COMPLETED
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
Novo Nordisk A/S n=834
NCT02582814 COMPLETED
The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
AstraZeneca n=151
NCT01109316 COMPLETED
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Eli Lilly and Company n=132
NCT02460978 COMPLETED
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
AstraZeneca n=815
NCT02414958 COMPLETED
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Boehringer Ingelheim n=730
NCT02034513 COMPLETED
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
Novo Nordisk A/S n=501
NCT03091673 COMPLETED
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
Xeris Pharmaceuticals n=31
NCT02580591 COMPLETED
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
Boehringer Ingelheim n=977
NCT02656069 COMPLETED
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
Xeris Pharmaceuticals n=80
NCT02268214 COMPLETED
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
AstraZeneca n=833
NCT03504046 COMPLETED
Safety and Feasibility Evaluation of the APS APP
Sansum Diabetes Research Institute n=6
NCT02059161 COMPLETED
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
Merck Sharp & Dohme LLC n=508
NCT01997411 COMPLETED
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Eli Lilly and Company n=48
NCT01581476 COMPLETED
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial
University of Cambridge n=443
NCT01792284 COMPLETED
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
Eli Lilly and Company n=212
NCT01454284 COMPLETED
A Study in Participants With Type I Diabetes Mellitus
Eli Lilly and Company n=1,114
NCT01481779 COMPLETED
A Study in Participants With Type 1 Diabetes Mellitus
Eli Lilly and Company n=455
NCT02735031 COMPLETED
Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes
Radboud University Medical Center n=10
NCT01194882 COMPLETED
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
Sanofi n=479
NCT02273180 COMPLETED
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=507
NCT01999322 COMPLETED
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Novo Nordisk A/S n=37
NCT00678886 COMPLETED
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
GlaxoSmithKline n=272
NCT01123083 COMPLETED
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
GlaxoSmithKline n=179
NCT01029392 COMPLETED
Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements
Corewell Health East n=75
NCT00642616 TERMINATED
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Mannkind Corporation n=34
NCT00982228 COMPLETED
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S n=629
NCT00773279 COMPLETED
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S n=242
NCT00978627 COMPLETED
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S n=548
NCT02045290 COMPLETED
Insulin Clamp Ancillary Study for Assessment of Insulin Resistance
Jaeb Center for Health Research n=37
NCT01074268 COMPLETED
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S n=456
NCT01836523 COMPLETED
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Novo Nordisk A/S n=1,398
NCT01079234 COMPLETED
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
Novo Nordisk A/S n=493
NCT01722227 WITHDRAWN
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
University at Buffalo
NCT02098395 COMPLETED
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
Novo Nordisk A/S n=835
NCT00891995 TERMINATED
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
Jaeb Center for Health Research n=71
NCT00623194 COMPLETED
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
Novo Nordisk A/S n=146
NCT02568501 COMPLETED
Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults
University of Pennsylvania n=90
NCT00760526 COMPLETED
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
Jaeb Center for Health Research n=146
NCT02705053 COMPLETED
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
Sansum Diabetes Research Institute n=32
NCT01103284 COMPLETED
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Andromeda Biotech Ltd. n=475
NCT01898286 TERMINATED
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
Andromeda Biotech Ltd. n=38
NCT01762657 WITHDRAWN
The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes
Perle Bioscience, Inc.
NCT01762644 WITHDRAWN
The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients
Perle Bioscience, Inc.
NCT02730949 COMPLETED
D-chiro-Inositol in Overweight Type 1 Diabetes Patients
Campus Bio-Medico University n=26
NCT01569841 COMPLETED
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Novo Nordisk A/S n=24
NCT01110746 COMPLETED
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
Biodel n=20
NCT02101229 COMPLETED
Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète n=17
NCT01683266 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Sanofi n=549
NCT02092896 COMPLETED
Liraglutide as add-on to Insulin in Type 1 Diabetes
Hvidovre University Hospital n=40
NCT01460251 TERMINATED
OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277
Rabin Medical Center n=11
NCT00729365 TERMINATED
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
Northwestern University n=65
NCT01517269 COMPLETED
PETS-D (Parent Education Thru Simulation-Diabetes)
University of Massachusetts, Worcester n=191
NCT01754181 COMPLETED
Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète n=18
NCT02097316 COMPLETED
Feasibility Study of the JewelPump Version 3
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète n=21
NCT01445951 COMPLETED
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Mannkind Corporation n=518
NCT01689129 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Sanofi n=243
NCT01223131 COMPLETED
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Sanofi n=162
NCT01497938 COMPLETED
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Medtronic MiniMed, Inc. n=247
NCT00644501 COMPLETED
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
Andromeda Biotech Ltd. n=43
NCT01134107 COMPLETED
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Eli Lilly and Company n=133
NCT01461616 COMPLETED
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis
University of Aarhus n=19
NCT00751842 TERMINATED
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
Diamyd Therapeutics AB n=331
NCT01550809 COMPLETED
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Fundación para la Investigación del Hospital Clínico de Valencia n=12
NCT00993473 COMPLETED
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
Sanofi n=125
NCT00723411 TERMINATED
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
Diamyd Therapeutics AB n=334
NCT00888732 COMPLETED
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin
University of Aarhus n=24
NCT01173991 COMPLETED
Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion
IRCCS San Raffaele n=61
NCT00758082 COMPLETED
Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients
University Hospital, Grenoble n=62
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only